Vitality Biopharma specializes in developing proprietary cannabinoid pharmaceuticals that comply with FDA and DEA regulations. The company focuses on creating oral cannabinoid medications, which are a convenient and desirable option for both patients and physicians. These pharmaceuticals aim to harness the full therapeutic potential of cannabinoid medicines while minimizing psychoactive side effects through targeted prodrug technology. Vitality operates in the pharmaceutical market, primarily serving patients with conditions such as IBD, NBS, MS, and neuropathic pain. The business model involves federally compliant drug development and the establishment of a specialty care treatment network in the United States, particularly aimed at reducing opioid dependence. Revenue is generated through the development and commercialization of these specialized cannabinoid drugs.

Keywords: cannabinoid pharmaceuticals, FDA compliance, DEA regulations, oral prodrugs, therapeutic potential, psychoactive reduction, opioid dependence, specialty care, drug development, neuropathic pain.